Evidence map›Paper›PMID 11094073›Full record

ArticleMolecular and cellular biology2000

Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

L Zeng, P Sachdev, L Yan, J L Chan, T Trenkle, M McClelland, J Welsh, L H Wang

Abstract read
In one paragraph

Article in Molecular and cellular biology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 143 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A rigorousFrontiers in molecular neuroscience · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Evaluation of Vav3.1 as prognostic marker in endometrial cancer.Journal of cancer research and clinical oncology · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

L ZengDepartment of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA.
P Sachdev
L Yan
J L Chan
T Trenkle
M McClelland
J Welsh
L H Wang
Icahn School of Medicine at Mount Sinai · USSidney Kimmel Cancer Center · USColumbia University · US

Funding

TRANSFORMING GENES OF AVIAN SARCOMA VIRUSESR01CA029339 · NCI · ROCKEFELLER UNIVERSITY · PI WANG, LU-HAI · 1985 to 2006
$2.3M
CELL TRANSFORMATION BY INSULIN AND IGFI RECEPTORSR01CA055054 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI WANG, LU-HAI · 1992 to 2002
$870k
NCI NIH HHS CA29339NCI NIH HHS CA55054NCI NIH HHS R01 CA029339NCI NIH HHS R01 CA055054
6 · The paper itself

Abstract

A recently reported new member of the Vav family proteins, Vav3 has been identified as a Ros receptor protein tyrosine kinase (RPTK) interacting protein by yeast two-hybrid screening. Northern analysis shows that Vav3 has a broad tissue expression profile that is distinct from those of Vav and Vav2. Two species of Vav3 transcripts, 3.4 and 5.4 kb, were detected with a differential expression pattern in various tissues. Transient expression of Vav in 293T and NIH 3T3 cells demonstrated that ligand stimulation of several RPTKs (epidermal growth factor receptor [EGFR], Ros, insulin receptor [IR], and insulin-like growth factor I receptor [IGFR]) led to tyrosine phosphorylation of Vav3 and its association with the receptors as well as their downstream signaling molecules, including Shc, Grb2, phospholipase C (PLC-gamma), and phosphatidylinositol 3 kinase. In vitro binding assays using glutathione S-transferase-fusion polypeptides containing the GTPase-binding domains of Rok-alpha, Pak, or Ack revealed that overexpression of Vav3 in NIH 3T3 cells resulted in the activation of Rac-1 and Cdc42 whereas a deletion mutant lacking the N-terminal calponin homology and acidic region domains activated RhoA and Rac-1 but lost the ability to activate Cdc42. Vav3 induced marked membrane ruffles and microspikes in NIH 3T3 cells, while the N-terminal truncation mutants of Vav3 significantly enhanced membrane ruffle formation but had a reduced ability to induce microspikes. Activation of IR further enhanced the ability of Vav3 to induce membrane ruffles, but IGFR activation specifically promoted Vav3-mediated microspike formation. N-terminal truncation of Vav3 activated its transforming potential, as measured by focus-formation assays. We conclude that Vav3 mediates RPTK signaling and regulates GTPase activity, its native and mutant forms are able to modulate cell morphology, and it has the potential to induce cell transformation.

Indexed as

Adaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportCell Cycle ProteinsCell SizeCell Transformation, Neoplastic3T3 CellsAnimalsBlotting, NorthernBlotting, WesternCell LineCulture Media, Serum-FreeGRB2 Adaptor ProteinGuanine Nucleotide Exchange FactorsHumansKidneyMiceAdaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportCell Cycle ProteinsCulture Media, Serum-FreeGRB2 Adaptor ProteinGRB2 protein, humanGrb2 protein, mouseGuanine Nucleotide Exchange FactorsPhosphatidylinositol 3-KinasesProteinsProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-vavReceptor Protein-Tyrosine KinasesReceptors, SomatomedinRecombinant Fusion Proteinsrho GTP-Binding ProteinsROS1 protein, humanRos1 protein, mouseSHC1 protein, humanShc1 protein, mouseShc Signaling Adaptor ProteinsSrc Homology 2 Domain-Containing, Transforming Protein 1Type C PhospholipasesVAV3 protein, humanVav3 protein, mouse

Identifiers

PMID11094073
PMCPMC102179
OpenAlexW2154683723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.